Skip to main content
Clinical Trials/NCT02127580
NCT02127580
Completed
N/A

Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry

Institut für Pharmakologie und Präventive Medizin7 sites in 1 country200 target enrollmentApril 2014

Overview

Phase
N/A
Intervention
Not specified
Conditions
Aortic Valve Stenosis
Sponsor
Institut für Pharmakologie und Präventive Medizin
Enrollment
200
Locations
7
Primary Endpoint
VARC2 criteria
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

There is limited experience for the balloon expandable THV (transcatheter heart valve) on the need for predilation (ballon aortic valvuloplasty, BAV). Therefore we aim to verify results of a small case series published by Wendler et. al. to examine hard endpoints such as the incidence of cerebrovascular complications, paravalvular leakage and operative outcomes in a multicenter registry.

We aim to compare the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

Detailed Description

Prior to the deployment of transcatheter heart valves (THV), balloon aortic valvuloplasty (BAV) is usually performed under rapid right ventricular pacing (burst \>180 bpm) with the induction of a functional cardiac arrest for up to 30 seconds. Aortic valve predilation is aiming at facilitating the crossing of the aortic annulus, accurate valve positioning and does also provide information on the anatomy of the valve complex. However, BAV has been shown to have a number of potentially detrimental effects, such as: * Functional cardiac arrest induced by rapid pacing leads to transient coronary, cerebral, and renal ischemia. * In patients with a reduced left ventricular ejection fraction (LVEF), prolonged cardiac depression after rapid pacing is observed and may result in hemodynamic failure and systemic inflammatory response syndrome (SIRS). Both are associated with a high periprocedural mortality. * BAV has been identified as a major source of thrombotic and valvular material and increases the risk for coronary obstruction with subsequent myocardial infarction and stroke. * The local trauma in the left-ventricular outflow tract caused by BAV may potentially contribute to aortic root rupture.

Registry
clinicaltrials.gov
Start Date
April 2014
End Date
May 2016
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Institut für Pharmakologie und Präventive Medizin
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with an indication for TAVI as to the Edwards THV IFU
  • Eligible for TABI with AND without BAV
  • Signed informed consent

Exclusion Criteria

  • Logistic EuroSCORE I \>50%
  • Mitral or tricuspid valvular insufficiency (\> grade II)
  • Previous aortic valve replacement
  • Uncontrolled atrial fibrillation
  • Left ventricular or atrial thrombus by echocardiography
  • Recent cerebrovascular event (within the last 3 months)
  • High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons)

Outcomes

Primary Outcomes

VARC2 criteria

Time Frame: 3 months

comparison of the implantation of balloon expandable transcatheter heart valves with or without predilation with respect to procedural outcomes (VARC2).

Study Sites (7)

Loading locations...

Similar Trials